Abstract
The aim of the study was to assess an effectiveness of S53P4 bioglass in reconstruction of postinflammatory bone loss. We have also evaluated wound healing after the surgical dead space management with use of the bioglass.
A group of 7 patients with bone loss due to active osteomyelitis and with purulent fistula treated with use of S53P4 bioglass is presented in the paper. All the treated patients were male with mean of age 40,5 years. Mean time of an active inflammatory process with purulent discharge from the wound prior the surgery was 587 weeks. Wound healing pattern with an X-ray evaluation of reconstructed void was performed in postoperative period as well as in 1, 3, 6 and 12 mounth follow-up.
In 6 out of 7 cases we did not observed any signs of infection recurrence in 1-year follow-up. Starting from 1-month follow-up inflammatory serum markers remained in their reference values. In all the successfully treated cases wound healing was assessed by two independent surgeons as excellent or good. Starting from 3-month follow-up we have observed gradual blurring of granular bioglass structure on an X-ray scans. In 1 complicated case we observed recurrence of septic inflammatory process with purulent fistula that required revision procedure with removal of the bioglass and extended debridement of inflammatory focus. In this case we have faced posttraumatic malunion of the femur that substantially complicated surgical access to the inflammatory focus during primary procedure.
S53P4 bioactive glass is an effective solution in reconstruction of postinflammatory bone loss. Properties of this biomaterial efficiently prevent from focal infection recurrence by inhibiting of bacterial bone growth and reduction of dead space. The product requires however meticulous debridement and the access to a vital bone as a source of osteoblast cells. Underestimation of surgical debridement will likely result in reopening of the fistula due to reinfection. The study group requires further evaluation.
